RGNT News
Regentis Biomaterials (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC (R), its proprietary implant for repairing damaged knee cartilage, in Israel. GelrinC has received regulatory approval from Israel’s Ministry of Health for the same indication […]
Investor Brand Network
Regentis Biomaterials (NYSE American: RGNT) Signs Four-Year Exclusive Distribution Agreement for GelrinC (R) in Israel
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC (R), its proprietary implant for repairing damaged knee cartilage, in Israel. GelrinC has received regulatory approval from Israel’s Ministry of Health for the same indication […]
Investor Brand Network
Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is […]
Investor Brand Network
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) […]
Investor Brand Network
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) […]
Investor Brand Network
Cartilage repair is intended to do more than simply reduce pain. Ideally, proper treatment should also restore the cartilage tissue responsible for the smooth movement and durability of a healthy joint. Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing a regenerative approach designed to address that challenge… Read More>> This content was disseminated on behalf […]
Investor Brand Network
For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance […]
Investor Brand Network
A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments […]
Investor Brand Network
Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for… Read More>> This content has been disseminated on behalf of Regentis Biomaterials Ltd. […]
Investor Brand Network
For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between […]
Investor Brand Network
Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual […]
Investor Brand Network